Author: Huang Rongqin Ma Haojun Guo Yubo Liu Shuhuan Kuang Yuyang Shao Kun Li Jianfeng Liu Yang Han Liang Huang Shixian An Sai Ye Liya Lou Jinning Jiang Chen
Publisher: Springer Publishing Company
ISSN: 0724-8741
Source: Pharmaceutical Research, Vol.30, Iss.10, 2013-10, pp. : 2549-2559
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
To prepare an angiopep-conjugated dendrigraft poly-L-lysine (DGL)-based gene delivery system and evaluate the neuroprotective effects in the rotenone-induced chronic model of Parkinson’s disease (PD).Angiopep was applied as a ligand specifically binding to low-density lipoprotein receptor-related protein (LRP) which is overexpressed on blood-brain barrier (BBB), and conjugated to biodegradable DGL via hydrophilic polyethyleneglycol (PEG), yielding DGL-PEG-angiopep (DPA).
Related content
Gene therapy for Parkinson’s disease: review and update
Expert Opinion on Investigational Drugs, Vol. 8, Iss. 10, 1999-10 ,pp. :
Transplantation therapy for Parkinson’s disease
Expert Opinion on Investigational Drugs, Vol. 9, Iss. 10, 2000-10 ,pp. :
Long-term results of ADA gene therapy
Inpharma, Vol. 1, Iss. 1388, 2003-01 ,pp. :